Literature DB >> 8386029

Interplay in vitro between ACTH, beta-endorphin, and glucocorticoids in the modulation of spontaneous and lymphokine-inducible human natural killer (NK) cell activity.

G Gatti1, R G Masera, L Pallavicini, M L Sartori, A Staurenghi, F Orlandi, A Angeli.   

Abstract

Release of pro-opiomelanocortin (POMC)-derived peptides and glucocorticoids characterizes the activation of the hypothalamic-pituitary-adrenal (HPA) axis and represents a major adaptive response to stress. Both glucocorticoids and POMC-derived hormones are known to be crucial modifiers of the immune response. Natural killer (NK) cells are a lymphocyte subset deeply involved in immunosurveillance. Cortisol, the most important glucocorticoid hormone in humans, is a well-established inhibitor, whereas the two lymphokines, immune interferon (IFN-gamma) and interleukin-2 (IL-2), are important physiological stimulators. In the present study, physiological as well as superphysiological concentrations of two POMC-derived peptides, ACTH and beta-endorphin, were shown not only to affect in vitro spontaneous and lymphokine-inducible NK activity of peripheral blood mononuclear (PBM) cells, but also to modify cortisol-mediated inhibition. NK activity was measured in a 4-h cytotoxic assay using the cell line K562 as a target, after prior incubation with ACTH (10(-8)-10(-12) M) and beta-endorphin (10(-8)-10(-14) M) in the presence or absence of cortisol (10(-6) M), IFN-gamma (325 IU/ml), and IL-2 (25 IU/ml). ACTH was ineffective in changing spontaneous NK activity at all concentrations, whereas beta-endorphin enhanced NK cytotoxicity (p < .02). The concomitant exposure of PBM cells to the two POMC-derived peptides and IFN-gamma or IL-2 significantly enhanced the lymphokine-induced boosting of NK activity. Moreover, ACTH and beta-endorphin were able to significantly reduce the cortisol-dependent inhibition (p < .05). These data are compatible with the hypothesis that POMC-derived peptides have a role in the modulation of NK cell activity. It seems likely that in cases of activation of the HPA axis, ACTH and beta-endorphin may effectively counteract the negative effects of glucocorticoids on NK cell activity, and prevent, at least in some instances, any overshooting of the glucocorticoid-dependent effect on immune cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8386029     DOI: 10.1006/brbi.1993.1002

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  5 in total

1.  Vitamin D, thyroid hormones and muscle mass influence natural killer (NK) innate immunity in healthy nonagenarians and centenarians.

Authors:  E Mariani; G Ravaglia; P Forti; A Meneghetti; A Tarozzi; F Maioli; F Boschi; L Pratelli; A Pizzoferrato; F Piras; A Facchini
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

2.  Chronic stress and susceptibility to skin cancer.

Authors:  Alison N Saul; Tatiana M Oberyszyn; Christine Daugherty; Donna Kusewitt; Susie Jones; Scott Jewell; William B Malarkey; Amy Lehman; Stanley Lemeshow; Firdaus S Dhabhar
Journal:  J Natl Cancer Inst       Date:  2005-12-07       Impact factor: 13.506

3.  Immune function of patients receiving recombinant human interleukin-6 (IL-6) in a phase I clinical study: induction of C-reactive protein and IgE and inhibition of natural killer and lymphokine-activated killer cell activity.

Authors:  C Scheid; R Young; R McDermott; L Fitzsimmons; J H Scarffe; P L Stern
Journal:  Cancer Immunol Immunother       Date:  1994-02       Impact factor: 6.968

4.  Possible stimulation of anti-tumor immunity using repeated cold stress: a hypothesis.

Authors:  Nikolai A Shevchuk; Sasa Radoja
Journal:  Infect Agent Cancer       Date:  2007-11-13       Impact factor: 2.965

5.  Direct effects of HP Acthar Gel on human B lymphocyte activation in vitro.

Authors:  Nancy J Olsen; Dima A Decker; Paul Higgins; Patrice M Becker; Carl A McAloose; Ann L Benko; William J Kovacs
Journal:  Arthritis Res Ther       Date:  2015-10-27       Impact factor: 5.156

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.